Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Rallybio Corporation

< Previous 1 2 Next >
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at Upcoming Investor Conferences
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
From Rallybio Corporation
Via Business Wire
Tickers RLYB
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at Upcoming Investor Conferences in November
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
From Rallybio Corporation
Via Business Wire
Tickers RLYB
Rallybio to Present at Upcoming Investor Conferences in September
From Rallybio Corporation
Via Business Wire
Tickers RLYB
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.